Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Autogene cevumeran |
Trade Name | |
Synonyms | RG 6180|RG-6180|RG6180|RO-7198457|RO 7198457|RO7198457|BNT 122|BNT-122|BNT122 |
Drug Descriptions |
Autogene cevumeran (RO7198457) is a personalized neoantigen-specific immunotherapy that stimulates T-cell mediated immune response against tumor cells, potentially resulting in antitumor activity (PMID: 37165196). |
DrugClasses | |
CAS Registry Number | 2365453-34-3 |
NCIT ID | C175745 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + Autogene cevumeran | Atezolizumab Autogene cevumeran | 0 | 2 |
Atezolizumab + Autogene cevumeran + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Atezolizumab Autogene cevumeran Fluorouracil Irinotecan Leucovorin Oxaliplatin | 0 | 2 |
Autogene cevumeran | Autogene cevumeran | 0 | 2 |
Autogene cevumeran + Pembrolizumab | Autogene cevumeran Pembrolizumab | 0 | 1 |